PALO ALTO, Calif.--(BUSINESS WIRE)--Open Monoclonal Technology, Inc. (OMT) today announced a license that
provides Amgen Inc. with access to OMT's proprietary OmniRat®,
OmniMouse® and OmniFlic(TM) human antibody generation platforms,
jointly known as OmniAb(TM). Amgen becomes OMT's 12th
non-academic partner globally with such multi-platform access.
Dr. Roland Buelow, OMT founder and CEO, said, "Amgen was an early
protein therapeutics leader and became one of a few companies with
transgenic mouse platforms for human antibody discovery in 2005 when
they acquired Abgenix and its XenoMouse®. With the license
from OMT, Amgen further builds on this capability as it gains access to
complementary platforms for development of fully human, mono- and
bispecific antibodies without any target restrictions."
About Open Monoclonal Technology, Inc.
Open Monoclonal Technology, Inc. (OMT) is a leader in genetic
engineering of animals for the generation of human therapeutic
antibodies, naturally optimized human antibodies®,
and the only company in the world with four transgenic animal platforms,
jointly known as OmniAb(TM).
OmniRat® is the industry's first
human monoclonal antibody technology based on rats. It has a complete
immune system with a diverse antibody repertoire and generates
antibodies with human idiotypes as well as wild-type animals make rat
antibodies. OmniMouse® is a
transgenic mouse that complements OmniRat and expands epitope coverage. OmniFlic(TM)
is an engineered rat with a fixed light chain for development of
bispecific, fully human antibodies. UniRat(TM)
is the first transgenic rat generating fully human heavy chain-only
antibodies and nanobodies for polyspecific applications.
All four OmniAb(TM) platforms deliver human antibodies with high affinity,
specificity, expression, solubility and stability. They use patented
technology, have broad freedom to operate and are available worldwide
for all targets and indications.
Current partners include Amgen, Caltech, Celgene, Chugai, Genmab,
Genentech, HanAll, Janssen, Merck KGaA, Pfizer, Roche, Symphogen,
University of Nottingham and several undisclosed biotech and
pharmaceutical companies. Animal hosting and OmniAb antibody discovery
services are available via Antibody Solutions, Panoply Bio and Sage Labs
in the US, Aldevron and Taconic Biosciences in Europe, and WuXi AppTec
in China. For more information, please visit www.omtinc.net.